Sigma Labs Inc (SASI): Maybe back in the day but IPQA has been...

VisionaryInc · 2014-11-16T00:15:00.6230000Z

Maybe back in the day but IPQA has been in SGLBs name since day one even going way back to Los Alamos. I dont see in this day and age GE trying to "pull a fast one" on anyone especially of this magnitude.

Play Episode

3min

Proactive - Interviews for investors

NSX CEO highlights mining focus & direct listings as key growth drivers for 2025

National Stock Exchange of Australia CEO Max Cunningham talked with Proactive's Angela Harmantas from the PDAC conference in Toronto about the exchange’s role in the Australian market, its focus on mining companies, and its expansion plans. Cunningham explained that the NSX is one of two active stock exchanges in Australia with a tier-one license, allowing it to serve all investors, including retail. He highlighted that around one-third of the exchange’s listings are mining-related, with strong growth potential in the sector. Cunningham noted that NSX is working to fill a gap in the Australian venture market and is focusing on attracting mining companies, especially from regions like Perth. He also emphasized the importance of international relationships, mentioning cross-listing agreements with Canadian exchanges such as the CSE and TSX, as well as OTC Markets. Looking ahead to 2025, Cunningham discussed the challenges of IPOs due to regulatory hurdles and capital-raising difficulties. Instead, the NSX is prioritizing direct listings, which allow companies to go public without raising capital upfront. He stated that NSX is seeing increased interest from firms moving from the incumbent Australian exchange, as well as from Canadian companies seeking dual listings. #NSX #StockMarket #MiningStocks #IPOs #DirectListings #PDAC2025 #Investing #AustralianMarkets #DualListings #CapitalMarkets

Proactive - Interviews for investors

Vinyl Group CEO on expansion, profitability & strategy after H1 revenue soars 770%

Vinyl Group Ltd CEO Josh Simons talked with Proactive's Jonathan Jackson about the company's strong financial growth, recent acquisitions, and future expansion plans. The company recently reported a 770.2% revenue increase in its latest half-year results. Simons highlighted the annual revenue run rate growth from $2 million to $20 million, emphasising that Vinyl Group is executing its aggressive acquisition strategy while optimising operations for profitability. A key topic of discussion was the acquisition of Concrete Playground, a move that expands Vinyl Group’s media and advertising reach. Simons explained that integrating Concrete Playground into the company’s existing infrastructure creates significant cross-selling opportunities whilst also strengthening Vinyl Group's market position. Looking ahead, Simons discussed the global expansion potential of Vinyl Group’s tech platforms. He noted that for the first time, the company’s tech segment outperformed its media business in revenue, signaling a shift toward scalable, international growth. “The pathway we’re on is clear—we’re optimising, moving towards profitability, and laying the groundwork for further expansion,” Simons said. For more interviews and updates, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for future updates. #VinylGroup #Music #MusicIndustry #JoshSimons #BusinessGrowth #TechExpansion #InvestorNews #MusicTech #ProactiveInvestors

Proactive - Interviews for investors

Pantheon Resources charts new course with leadership transition naming new CEO

Pantheon Resources is entering a pivotal phase as it refines its strategic direction under new leadership. Executive Chairman David Hobbs and newly appointed CEO Max Easley recently spoke with Steve Darling from Proactive, offering insights into the company’s transition and future plans. Hobbs, who is shifting from executive to non-executive chairman, expressed deep appreciation for Jay Cheatham’s 17 years of dedicated service to the company. Meanwhile, Easley, a seasoned industry veteran with over 30 years of experience at BP, Apache and PETRONAS, conveyed his excitement about leading Pantheon Resources at such a critical juncture. A native of Alaska, Easley is particularly drawn to the opportunity to develop Pantheon’s substantial assets in his home state. “Two billion barrels in my own backyard. It’s amazing,” he remarked, underscoring his confidence in the company’s potential. His extensive expertise in both conventional and unconventional oil positions him well to steer the company through its next phase of growth. Looking ahead, Hobbs outlined key milestones for Pantheon and an anticipated surge in company updates. The company’s Annual General Meeting (AGM) is scheduled for March 12, and stakeholders can expect a steady flow of developments. He emphasized the significant progress made over the past 18 months, from securing a path to financing through the agreement with ADC to advancing the Megrez well. As Pantheon transitions from exploration to production, Easley assured investors that momentum is building. “Expect activity followed by good results,” he said, signalling confidence in the company’s trajectory. With strong leadership and a clear strategy, Pantheon Resources is poised for a dynamic and productive year ahead. #proactiveinvestors #pantheonresourcesplc #mining #lse #panr #pthrf #MaxEasley #DavidHobbs #OilAndGas #AlaskaEnergy #CEOInterview #OilProduction #InvestorNews #EnergySector #ProactiveInvestors

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Followers	27
Posts	3261
Boards Moderated	1
Alias Born	06/27/2014

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free